← 研踪 PaperTrailarXiv:2609.26105 · v2
Neoadjuvant chemotherapy response prediction using pretreatment diffusion and contrast-enhanced magnetic resonance imaging with clinical variables
首次提交 2026-08-18 19:52
版本更新 2026-11-18 03:32
雷达观测 2026-11-19 19:08
摘要
Prediction of pathological complete response before neoadjuvant chemotherapy may facilitate more tailored therapeutic planning for breast cancer patients. This work proposes a deep-learning model for pretreatment data only, combining apparent diffusion coefficient maps, dynamic contrast-enhanced magnetic resonance imaging, and clinical variables. The study uses the public ACRIN 6698/I-SPY2 multicenter dataset. The architecture employs EfficientNet-B0 pretrained encoders for image feature extraction and late fusion with clinical information. Multiple clinical variables were evaluated, including age, race, histological type, HR/HER2 subtype, SBR grade, and maximum diameter. Only HR/HER2 subtype improved the average area under the receiver operating characteristic curve (AUC) and was retained in the final model. Using stratified five-fold cross-validation, standalone apparent diffusion coefficient maps achieved a mean AUC of 0.79, whereas dynamic contrast-enhanced magnetic resonance imaging achieved 0.74. Adding HR/HER2 subtype improved performance to 0.83 and 0.81, respectively. The final configuration, using both imaging modalities and HR/HER2 subtype, achieved an AUC of 0.86. These results support pretreatment multimodal learning for response prediction, although external validation is required before clinical use.
作者备注:Under consideration at Pattern Recognition Letters. 7 Pages, 2 figures, 3 tables
观测到的版本
相邻记录可能跳过中间版本;首次发现 v2 及以上也会标为版本更新。
v2 · 2026-11-18 03:32 · 最新观测版本
Neoadjuvant chemotherapy response prediction using pretreatment diffusion and contrast-enhanced magnetic resonance imaging with clinical variables
Prediction of pathological complete response before neoadjuvant chemotherapy may facilitate more tailored therapeutic planning for breast cancer patients. This work proposes a deep-learning model for pretreatment data only, combining apparent diffusion coefficient maps, dynamic contrast-enhanced magnetic resonance imaging, and clinical variables. The study uses the public ACRIN 6698/I-SPY2 multicenter dataset. The architecture employs EfficientNet-B0 pretrained encoders for image feature extraction and late fusion with clinical information. Multiple clinical variables were evaluated, including age, race, histological type, HR/HER2 subtype, SBR grade, and maximum diameter. Only HR/HER2 subtype improved the average area under the receiver operating characteristic curve (AUC) and was retained in the final model. Using stratified five-fold cross-validation, standalone apparent diffusion coefficient maps achieved a mean AUC of 0.79, whereas dynamic contrast-enhanced magnetic resonance imaging achieved 0.74. Adding HR/HER2 subtype improved performance to 0.83 and 0.81, respectively. The final configuration, using both imaging modalities and HR/HER2 subtype, achieved an AUC of 0.86. These results support pretreatment multimodal learning for response prediction, although external validation is required before clinical use.
查看此版本解读 →查看此版本原文 ↗